WEX Pharmaceuticals Inc. is engaged in the discovery, development, manufacture and commercialization of drug products treat pain management. The Company’s platform is tetrodotoxin (TTX), a selective sodium channel blocker. Its product based on TTX is in Phase III clinical development for the treatment of cancer-related pain. As of December 31, 2010, it has completed five clinical trials with TTX, with more than 200 patients treated. The Company products include TTX for cancer-related pain, TTX for chemotherapy-induced neuropathic pain and Scientific Publications. The Company’s TEC-006 is a clinical trial for the treatment of moderate to severe inadequately controlled cancer-related pain. Its TTX-CINP-201 is a clinical trial for the treatment of moderate to severe neuropathic pain caused by chemotherapy in patients with cancer. The Company is a subsidiary of CK Life Sciences Int’l., (Holdings) Inc. (CKLS).